Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

0
Player Avatar portefeuille (99.75) Submitted: 12/15/2011 10:56:38 PM : Outperform Start Price: $102.70 BIIB Score: +29.31

There are currently 270 BIIB shares in my "fund" with break-even of around 71.89 USD. http://caps.fool.com/Blogs/fund-trades/678775.

Featured Broker Partners


Advertisement